IBCN publications - meeting reports - selected collaborative topic papers

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. 2018 Mar 13. pii: S1078-1439(17)30591-4. doi: 10.1016/j.urolonc.2017.11.006. [Epub ahead of print]

Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, Nawroth R. CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer 3 (2017) 79–88

Schmitz-Dräger C, Bonberg N, Pesch B, Todenhöfer T, Sahin S, Behrens T, Brüning T, Schmitz-Dräger BJ. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. Urol Oncol. 2016 Oct;34(10):452-9.

Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urol Oncol. 2016 Oct;34(10):469-76.

Vlahou A, Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Taking the next step-Advancing bladder cancer management. Urol Oncol. 2016 Oct;34(10):435-6.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. Urol Oncol. 2016 Oct;34(10):437-51.

Kassouf W, Traboulsi SL, Schmitz-Dräger B, Palou J, Witjes JA, van Rhijn BW, Grossman HB, Kiemeney LA, Goebell PJ, Kamat AM. Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations. Urol Oncol. 2016 Oct;34(10):460-8.

Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ. Current concepts-future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012. Urol Oncol. 2014,32:1049-50.

Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ. Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol. 2014,32:1051-60.
Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A,Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R,Grossman HB, Sanchez-Carbayo M, Kamat A. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol. 2014,32:1061-8.
Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol. 2014,32:1069-77.
van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeney LA. Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urol Oncol. 2014,32:1078-87.
Grossman HB, Dinney CPN, Schmitz-Dräger BJ, Goebell PJ. The International Bladder Cancer Network - Current Perspectives in Bladder Cancer. Urol Oncol. 2010, 28:375-376.
Goebell PJ, Groshen SG, Schmitz-Dräger BJ and International Study-Initiative on Bladder Cancer (ISBC). p53 immunohistochemistry in bladder cancer--a new approach to an old question. Urol Oncol. 2010,28:377-388.
Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010,28:389-400.
Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010,28:401-408.
Goebell PJ and Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol. 2010,28:409-428.
McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010,28:429-440.
Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJP, Stöhr B, Bassi PF, Grossman HB. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010,28:441-448.
Goebell PJ and Morente MM. New concepts of biobanks - strategic chance for uro-oncology. Urol Oncol. 2010,28:449-457.
Schmitz-Dräger BJ, Fradet Y and Grossman HB: Bladder cancer markers in patient management: the current perspective. World J Urol. 2008;26:1-3.
Goebell PJ, Groshen SL and Schmitz-Dräger BJ: Guidelines for development of diagnostic markers in bladder cancer. World J Urol. 2008;26:5-11.
Lotan Y, Svatek RS and Malats N: Screening for bladder cancer: a perspective? World J Urol. 2008;26:13-18.
Madeb R and Messing EM: Long-term outcome of home dipstick testing for hematuria. World J Urol. 2008;26:19-24.
Chiong E, Gaston KE and Grossman HB: Urinary markers in screening patients with hematuria. World J Urol. 2008;26:25-30.
Schmitz-Dräger BJ, Tirsar LA, Schmitz-Dräger C, Dörsam J, Mellan Z, Bismarck E and Ebert T: Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol. 2008;26:31-7.
Agarwal PK, Black PC and Kamat AM: Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008;26:39-44.
Raitanen MP and The FinnBladder Group: The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol. 2008;26:45-50.
Nguyen CT and Jones JS: Defining the role of NMP22 in bladder cancer surveillance. World J Urol. 2008;26:51-8.
Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. Concepts for banking tissue in urologic oncology - the International Bladder Cancer Bank. Clin Cancer Res. 2005;11:413-5.
Schmitz-Dräger BJ, Malats N and Bassi PF: Predictive medicine in urology. World J Urol. 2004;21:365-8.
Mancini M, Cisternino A, Tavolini IM, Dal Moro F and Bassi PF: Predictive medicine in non-malignant urological disorders. World J Urol. 2004;21:369-376.
Hemminki K, Li X and Czene K: Familial risk of urological cancers: data for clinical counseling. World J Urol. 2004;21:377-381.
Golka K, Wiese A, Assennato G and Bolt HM: Occupational exposure and urological cancer. World J Urol. 2004;21:382-391.
Zeegers MPA, Kellen E, Buntinx F and Brandt PA: The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21:392-401.
Sommer F, Klotz T and Schmitz-Dräger BJ: Lifestyle issues and genitourinary tumours. World J Urol. 2004;21:402-413.
Goebell PJ, Villanueva CM, Rettenmeier AW, Rübben H and Kogevinas M: Environmental exposure, chlorinated drinking water, and bladder cancer World J Urol. 2004;21:424-432.
MaxwellJ. Mehlman MJ: Predictive genetic testing in urology: ethical and social issues. World J Urol. 2004;21:433-437.
Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Waldman F, Cote RJ. The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol. 2004;22:277-84.
Grossman HB. The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. Urol Oncol. 2000;5:183-4.
Witjes JA, Kiemeney L, Wheeless LL, Grossman HB: The value of histopathological prognostic factors in superficial bladder cancer: Do we need more? Urol Oncol. 2000;5:185-190.
Reznikoff CA, Sarkar S, Jülicher KP, Burger MS, Puthenveettil JA, Jarrard DF, Newton MA: Genetic alterations and biological pathways in human bladder cancer pathogenesis.Urol Oncol. 2000;5:191-203.
Schmitz-Dräger BJ, Goebell PJ, Heydthausen M, International Study Initiative on Bladder Cancer (ISBC): p53 immunohistochemistry in bladder cancer: Combined analysis: a way to go? Urol Oncol. 2000;5:204-10.
Faraggi D, Kramar A: Methodological issues associated with tumor marker development: Biostatistical aspects. Urol Oncol. 2000;5:211-13.
Taube SE, Freiberg GP: Regulatory issues related to marker development.Urol Oncol. 2000;5:214-6.
McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, Grossman HB, Peng A, Taube SE, Waldman FM. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res. 2000;6:1854-64.


Druckversion Druckversion | Sitemap
(last update:19-MAR-2015)